article thumbnail

WORLD’S LARGEST BROWSABLE RESOURCE LINKING RARE PROTEIN-CODING GENETIC VARIANTS TO HUMAN HEALTH AND DISEASE

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). These genetic data have been paired with detailed health information to create this browsable resource.

article thumbnail

Collaboration between AbbVie, Biogen and Pfizer creates world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease

The Pharma Data

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. About the UK Biobank. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). For more than 170 years, we have worked to make a difference for all who rely on us.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

University of Melbourne reveals design of new infectious disease institute

Pharmaceutical Technology

The new AIID building will include a human infection challenge unit, high-containment facilities, a robotic biobanking facility, interview rooms, dry laboratories and spaces for community engagement and co-design work. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

article thumbnail

A new dawn of the genomic age: five areas set to be transformed in 2023

pharmaphorum

The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers. This includes uncovering novel isoforms, fusions, and structural variants – the main drivers of cancer.

Genome 129
article thumbnail

GSK pumps £30m into a new Oxford University partnership

pharmaphorum

The project is further evidence of a re-entry by GSK into neuroscience, a category that it has largely retreated from over the last decade in favour of investing more in cancer, vaccines and infectious disease, immunology and respiratory medicines. ” The post GSK pumps £30m into a new Oxford University partnership appeared first on.

article thumbnail

How COVID-19 Has Permanently Changed The World of Medical Research

The Pharma Data

A spirit of urgency and collaboration broke down traditional informational barriers as industry and academia organized like never before in modern history to develop a vaccine in just nine months. . I think it’s also important to think about the definition of biobanks. These should not be museums where samples are archived.

article thumbnail

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

The Pharma Data

The UK biobank released a further dataset on COVID-19 positive patients consisting of ~4,000 confirmed COVID-19 infected patients in November 2020. The Company also anticipates that the knowledge gained may provide valuable insight for the development of a broadly applicable infectious-disease susceptibility model in the future.